Web of Science: 31 cites, Scopus: 33 cites, Google Scholar: cites,
Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Hamelmann, H. (Berlin Institute of Health. Department of Hematology and Oncology)
Palomo, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Mir, Enrique (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Moreno-Castaño, Ana Belén (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Torramade, S. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Rovira, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Escolar, Ginès (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Cordes, Steffen (Berlin Institute of Health. Department of Hematology and Oncology)
Kalupa, Martina (Berlin Institute of Health. Department of Hematology and Oncology)
Mertlitz, S. (Berlin Institute of Health. Department of Hematology and Oncology)
Riesner, K. (Berlin Institute of Health. Department of Hematology and Oncology)
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Penack, O. (Berlin Institute of Health. Department of Hematology and Oncology)
Diaz-Ricart, Maribel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Universitat Autònoma de Barcelona

Data: 2019
Resum: Angiogenesis and endothelial activation and dysfunction have been associated with acute graft-vs. -host disease (aGVHD), pointing to the endothelium as a potential target for pharmacological intervention. Defibrotide (DF) is a drug with an endothelium-protective effect that has been approved for the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Clinical data suggest that DF also reduces the incidence of aGVHD; however, the mechanisms of DF-mediated aGVHD regulation have not been examined. To investigate possible DF-mediated prophylactic and therapeutic mechanisms in aGVHD, we performed in vitro studies using endothelial cell (EC) lines. We found that DF significantly and dose-dependently suppressed EC proliferation and notably reduced their ability to form vascular tubes in Matrigel. To explore whether DF administered prophylactically or therapeutically has a significant effect on aGVHD endothelial dysfunction, ECs were exposed to media containing sera from patients with aGVHD (n = 22) in the absence or presence of DF and from patients that did not develop aGVHD (n = 13). ECs upregulated adhesion molecules (vascular cell adhesion molecule 1, intercellular adhesion molecule 1), the adherence junction protein VE-cadherin, von Willebrand factor (VWF), and Akt phosphorylation in response to aGVHD sera. These responses were suppressed upon treatment with DF. In summary, DF inhibits vascular angiogenesis and endothelial activation induced by sera from aGVHD patients. Our results support the view that DF has notable positive effects on endothelial biology during aGVHD.
Ajuts: Instituto de Salud Carlos III PI19-00888
Instituto de Salud Carlos III PIE15-00027
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR671
Instituto de Salud Carlos III DTS16-00133
Nota: Altres ajuts: This study was supported in part by Jazz Pharmaceuticals Plc (IST-16-10355), German Jose Carreras Leukaemia Foundation (11R/2016 and 03R/2019).
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Cute GVHD ; Angiogenesis ; Defibrotide ; Hematopoietic cell transplantation
Publicat a: Frontiers in immunology, Vol. 10 (september 2019) , p. 2339, ISSN 1664-3224

DOI: 10.3389/fimmu.2019.02339
PMID: 31649666


11 p, 2.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2021-02-26, darrera modificació el 2023-09-04



   Favorit i Compartir